Spero Therapeutics (SPRO) Shareholder's Equity Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.54% |
| Dec 31, 2025 | 27.96% |
| Sep 30, 2025 | -59.56% |
| Jun 30, 2025 | -59.22% |
| Mar 31, 2025 | -64.87% |
| Dec 31, 2024 | -56.85% |
| Sep 30, 2024 | 21.98% |
| Jun 30, 2024 | 46.95% |
| Mar 31, 2024 | 48.44% |
| Dec 31, 2023 | 40.77% |
| Sep 30, 2023 | 65.33% |
| Jun 30, 2023 | 52.50% |
| Mar 31, 2023 | 3.79% |
| Dec 31, 2022 | -13.99% |
| Sep 30, 2022 | -70.97% |
| Jun 30, 2022 | -60.20% |
| Mar 31, 2022 | -47.43% |
| Dec 31, 2021 | -33.13% |
| Sep 30, 2021 | -15.73% |
| Jun 30, 2021 | 22.44% |
| Mar 31, 2021 | 44.18% |
| Dec 31, 2020 | 77.06% |
| Sep 30, 2020 | 42.73% |
| Jun 30, 2020 | -32.79% |
| Mar 31, 2020 | -27.27% |
| Dec 31, 2019 | -35.63% |
| Sep 30, 2019 | -25.90% |
| Jun 30, 2019 | 67.01% |
| Mar 31, 2019 | 51.31% |
| Dec 31, 2018 | 36.37% |
| Sep 30, 2018 | 253.42% |
| Dec 31, 2017 | 272.51% |